[Biotech&Pharma] Why This Highly Rated Biotech Stock Jumped As High As 26%

Browse By

Shares of Clovis Oncology (CLVS) jumped Wednesday after U.S. regulators accepted the biotech company's application for a prostate cancer treatment.


{“@context”:”https://schema.org”,”@type”:”VideoObject”,”name”:”Investing Strategies: Positioning Your Portfolio For Q4 And Beyond”,”description”:”With global growth concerns and signals of economic softness here at home, this week it's all about how to position your holdings for Q4 and beyond. Edward Jones shares insights about the asset classes you should be watching and why you shouldn't play politics with your portfolio. Caliber Financial shares ETF strategies that focus on growth and aim for stabilization in today's volatile market. Plus, we analyze the chart of an international standout that's forming a rare, bullish pattern.”,”thumbnailUrl”:”https://www.investors.com/wp-content/uploads/2019/10/BJmpaWu2-640×360.jpg”,”contentUrl”:”https://content.jwplatform.com/manifests/BJmpaWu2.m3u8″,”uploadDate”:”2019-10-14T13:48:55+0000″,”duration”:”PT1330.42S”,”author”:”ALISSA CORAM”,”publisher”:{“@type”:”Organization”,”name”:”Investor's Business Daily”,”logo”:{“@type”:”ImageObject”,”url”:”https://www.investors.com/wp-content/uploads/2018/09/ibd-logo.png”},”url”:”https://www.investors.com”},”keywords”:””}

On today's stock market, Clovis stock rose 6%, to 9.43, in above-average volume. Earlier, the stock catapulted as high as 25.6%. Shares have a strong Relative Strength Rating of 94 out of a possible 99. The RS Rating measures a stock's 12-month performance.

The biotech company is hoping to use a drug called Rubraca to treat men with prostate cancer that can't be cured through castration. Patients must have a mutation in the BRCA 1 or BRCA 2 genes, and have cancer that has not only recurred, but spread.

Food and Drug Administration regulators also granted Rubraca priority review in prostate cancer treatment. The FDA set the review date for May 15.

“We are encouraged by the FDA's decision to grant priority review to the Rubraca application, which focuses on eligible patients with advanced prostate cancer, for whom new treatment options are very much needed,” Chief Executive Patrick Mahaffy said in a written statement.

Large Prostate Cancer Treatment Market

Rubraca belongs to a class of drugs called PARP inhibitors. It competes against drugs from pharma giants GlaxoSmithKline (GSK) and AstraZeneca (AZN). AstraZeneca makes Lynparza and GlaxoSmithKline owns Zejula through its takeover of biotech company Tesaro.

Clovis' Rubraca is a maintenance treatment for ovarian cancer patients. Physicians can also use it as a third option for ovarian cancer patients after chemotherapy.

Prostate cancer treatment would open up a new market for Clovis. Roughly 43,000 men in the U.S. are expected to be diagnosed with metastatic castration-resistant prostate cancer in 2020, the biotech company said in a news release.

The American Cancer Society estimated more than 175,000 men in the U.S. received a prostate cancer diagnosis in 2019. Globocan Cancer Fact Sheets estimates about 450,000 men in Europe had prostate cancer in 2018, Clovis said.

Follow Allison Gatlin on Twitter at @IBD_AGatlin.


Medtech CEO Bullish After Preliminary Fourth-Quarter Report Disappoints

Tesla Stock Extends Surge As Wall Street Sees Brighter Picture

Leaderboard Rose 11% As The 2018 Market Sank. Sign Up For A Free Trial

Want More IBD Insights? Subscribe To Our Investing Podcast!

Stocks To Buy And Watch: Top IPOs, Big And Small Caps, Growth Stocks

The post Why This Highly Rated Biotech Stock Jumped As High As 26% appeared first on Investor's Business Daily.

Source Investor’s Business Daily

This news is provided by Investor’s Business Daily RSS Feed, All credits go to Investor’s Business Daily. For more Investor’s Business Daily News please visit: https://www.investors.com/

Disclaimer: All posts made on this website are provided for information purposes only. None of the information here is intended as investment advice, as an offer or solicitation of an offer to buy or sell, or as a recommendation, endorsement, or sponsorship of any security, Company, or fund. Before making an investment decision, you should seek the advice of a qualified and registered securities professional. The author is not paid to share this information. Cannabis Investment Group is not paid to share this information and has no business relationship other than shareholder with any company whose stock is mentioned in this article.

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.